Beauvericin and enniatins H, I and MK1688 are new potent
inhibitors of human immunodeficiency virus type-1 integrase
The Journal of Antibiotics (2009) 62, 687–690
Cha-Gyun Shin, Dog-Gn An1, Hyuk-Hwan Song and Chan Lee
Department of Biotechnology, BET Research Institute, Chung-Ang
University, Anseong, Gyeonggi, South Korea; Department of
Food Science and Technology, BET Research Institute, Chung-Ang
University, Anseong, Gyeonggi, South Korea
Correspondence: Dr C Lee, Department of Food Science and
Technology, Chung-Ang University, Anseong, Gyeonggi 456-756,
South Korea. E-mail:
chanlee@cau.ac.kr
Some enniatins reportedly exhibit antiretroviral
activities in vivo. The potential inhibitory activities of
cyclic hexadepsipeptides such as beauvericin and Enniatins
H, I and MK1688 were investigated in vitro against human
immunodeficiency virus type-1 (HIV-1) integrase and Moloney
murine leukemia virus reverse transcriptase. Beauvericin ,
Enniatin I and Enniatin MK1688 exhibited strong inhibitory
activities against HIV-1 integrase, whereas Enniatin H showed
relatively weak activity. None of the examined compounds showed
anti-reverse transcriptase activity. Beauvericin was the most
effective inhibitor of the tested cyclic hexadepsipeptides in
inhibiting HIV-1 integrase. These results indicate the potential
of cyclic hexadepsipeptides as a new class of potent inhibitors
of HIV-1 integrase
|
